Korea and Japan: Two Regulatory Approaches to Cellular Therapy

The reader who has spent a measured afternoon comparing Seoul and Tokyo for a regenerative-medicine trip will have noticed, somewhere in the second hour of reading, that the two cities offer the same broad treatment category through rather differently drawn regulatory frames. Korea and Japan are the two East Asian jurisdictions a cosmopolitan patient is most likely to weigh against each other for cellular therapy, and the framing the consumer press tends to favour — Korea is permissive, Japan is strict, choose one — flattens a distinction that on careful reading rewards a slower read. Both jurisdictions regulate. Both have approved products. Both run active clinical-trial registries. The two frameworks differ in their architecture, in their default permissions, and in what they ask of the patient at the threshold of consent — and the differences are exactly the sort the discreet reader is well served by holding in view before any consultation. 兩邊都有規矩，只係規矩唔同, as a Hong Kong physician put it to me over yum cha — both sides have rules, only the rules differ.

The two frameworks at a glance

Korea regulates cellular therapy through a stack one might describe as conventional pharmaceutical-and-device architecture overlaid with the foreign-patient registration administered by KHIDI. Cellular products — autologous preparations, allogeneic mesenchymal stem cell products, exosome preparations, conditioned media — fall, in the regulatory reading, into the category the Ministry of Food and Drug Safety, known as MFDS, administers under the Pharmaceutical Affairs Act and the Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products, the latter known in shorthand as the Advanced Regenerative Medicine Act. Approved products carry a documented approval; clinical-trial-stage products operate within a clinical-trial framework; minimally manipulated autologous preparations sit in a slightly differently drawn category that the careful reader should ask the clinic to clarify. The architecture is, in editorial reading, recognisable from other developed-jurisdiction pharmaceutical regulation, with a regenerative-medicine specific overlay added in 2020.

Japan regulates cellular therapy through what the comparative literature has come to call a two-track system, established in 2014 under a pair of paired statutes — the Pharmaceuticals and Medical Devices Act, known as PMD Act, and the Act on the Safety of Regenerative Medicine, known as ASRM. The first track handles cellular products as approved or trial-stage pharmaceutical-equivalent products. The second track is what makes Japan distinctive in the global regulatory landscape: a framework that permits, under a documented certification process, clinics to administer regenerative-medicine treatments outside the formal pharmaceutical-product approval pathway, classified by risk tier and overseen by certified committees. The architecture is rather more particular to Japan than the consumer press generally captures, and the cosmopolitan reader is well served by understanding it as a deliberate regulatory choice rather than a permissive accident. A 2022 review in Cell Stem Cell described the Japanese framework as the most explicit dual-track architecture among advanced-economy jurisdictions, though the field continues to debate how the two tracks compare on outcome data.

Korea: the conventional architecture

The Korean framework, on careful reading, sits within what one might call the global mainstream of pharmaceutical regulation. A cellular product brought to clinical use must, as a general matter, hold MFDS approval — the Korean equivalent, in editorial register, of FDA or EMA approval — issued under a documented review process that examines manufacturing, characterisation, preclinical data, and clinical outcomes through an investigational pathway. Products in clinical trial operate under MFDS-issued investigational new drug status. Minimally manipulated autologous preparations — fresh harvest, same-day processing, return to the donor patient — sit in a slightly differently drawn category that varies by indication and processing depth. The framework is, in the comparative reading, similar in shape to the United States and European architectures, with regional adaptations in the regenerative-medicine specific provisions added in the 2020 Advanced Regenerative Medicine Act.

What the cosmopolitan reader will encounter in a well-run Korean clinic is the practical expression of this architecture. An allogeneic mesenchymal stem cell product on offer should carry a traceable provenance — supplier, lot number, certificate of analysis, MFDS approval status if applicable, or documented investigational status if the product is in trial. An autologous protocol should specify the harvest depot, the processing method, the regulatory category under which the preparation is administered, and the expected yield characteristics. The clinic that walks the patient through this documentation in measured terms before consent is operating within the framework as it was designed; the clinic that becomes evasive at the request, or appeals to clinical experience as a substitute for documentation, is communicating something the patient should hear. The careful reader who has read the MFDS English portal before consultation arrives with the right vocabulary for the conversation — and the conversation, in turn, generally goes better.

Japan: the dual-track distinction

The Japanese framework is the one that rewards the most careful reading from the patient's seat, partly because the consumer press tends to flatten the dual-track architecture into a single permissive narrative the actual statute does not support. The first track — the PMD Act track — runs in shape similar to the Korean MFDS architecture: pharmaceutical-equivalent approval, clinical-trial framework, manufacturing standards, lot release. Several allogeneic mesenchymal stem cell products and induced pluripotent stem cell preparations have come to market through this track, including products approved through the conditional time-limited approval pathway introduced in the 2014 reform. The second track — the ASRM track — is the distinctive one, and it permits, under documented certification by a Special Committee for Regenerative Medicine and notification to the relevant regional bureau, the administration of cellular therapy outside the formal product approval pathway, classified by risk tier into Class I, II, or III provisions.

The ASRM track is sometimes read in the consumer press as a permissive shortcut. On careful reading, it is a different regulatory architecture rather than a permissive one — the certification process requires documentation of the protocol, oversight by a credentialed committee, adverse-event reporting, and ongoing compliance review. What the architecture does, importantly, is permit a wider range of indication-and-protocol combinations to reach clinical practice without each combination passing through the full pharmaceutical-product approval gauntlet, on the regulatory reasoning that some such treatments — particularly autologous and minimally manipulated — sit in a category that the conventional product-approval pathway is not optimally suited to govern. The cosmopolitan reader should not, on this reading, treat ASRM-track treatments as inherently inferior to PMD Act track treatments; the question is, rather, which architecture the specific protocol on offer is operating within, and what oversight that architecture imposes. A 2023 paper in Regenerative Therapy summarised the Class I, II, III distinctions and noted, on careful reading, that the patient-protective architecture varies meaningfully across the three tiers — Class I, the highest-risk tier, requiring the most demanding committee review.

What ASRM Class tiers signify

Class I covers higher-risk procedures including those involving genetically modified cells, allogeneic preparations, and treatments outside the donor's homologous use. Class II covers somewhat lower-risk autologous procedures with substantive manipulation. Class III covers minimally manipulated autologous procedures of homologous use. The committee review intensity, the notification depth, and the ongoing compliance burden vary across the three. The cosmopolitan reader contemplating an ASRM-track treatment in Japan should ask, before consent, which class the protocol falls into.

How the two frameworks read from the patient's seat

The cosmopolitan patient's question, before any other, is rarely the regulator's question — it is, instead, what does this framework ask of me, and what does it offer me, at the moment of consent. The Korean framework, on careful reading, asks the patient to verify product approval status, to confirm clinic registration through KHIDI, to document the cell-source and processing pathway, and to clarify the indication-protocol fit before consent. What it offers, in return, is the documented threshold of MFDS approval for the product, the regulated indemnity floor through KHIDI registration, and the structural pathway for redress through both agencies. The architecture is recognisable, the documentation is verifiable, and the patient's verification work is largely a matter of asking the right questions and holding the right documents in view.

The Japanese framework, on careful reading, asks the patient for a slightly different verification arc. The PMD Act track verification reads similar in shape to the Korean MFDS verification — approval status, lot certification, indication-protocol fit. The ASRM track verification asks the patient to verify the certification documentation of the protocol itself, the class tier into which it falls, the credentialing of the Special Committee that reviewed it, and the adverse-event reporting framework under which it operates. What the framework offers, in return, is the wider availability of certain indication-protocol combinations the conventional product-approval pathway has not yet reached, alongside an oversight architecture that is meaningfully present rather than absent. The patient's verification work is, in editorial reading, slightly more involved than the Korean equivalent — but it is verification work that the framework supports rather than obscures, and the well-run Japanese clinic walks the patient through the documentation as a routine matter.

Where the two converge — and where they don't

The convergences between the two frameworks are, on careful reading, more substantial than the comparative narrative tends to capture. Both jurisdictions regulate cellular products under recognisable advanced-economy architecture. Both have approved allogeneic mesenchymal stem cell products in current clinical use. Both maintain active investigational pathways and clinical-trial registries. Both impose adverse-event reporting obligations. Both administer foreign-patient registration frameworks — Korea's KHIDI and Japan's pair of certifications, the JIH and JMIP — through which the cosmopolitan patient receives a documented set of patient-protective equivalents that home jurisdictions do not, as a general matter, follow them across borders to provide. The two frameworks share, in editorial register, more architecture than the press tends to allow, and the cosmopolitan reader who treats one as inherently more rigorous than the other has, on careful reading, mistaken architectural difference for substantive gap.

The divergences are real and worth holding distinct in mind. Japan's ASRM track admits a category of clinical practice the Korean framework, in its current form, generally does not — particularly the broader range of autologous and minimally manipulated protocols that the Class III tier governs. Korea's framework, on the other hand, has integrated the foreign-patient registration architecture more fully into the standard clinical workflow, in part because the Korean health-industry strategy has positioned foreign-patient care as a deliberate sector. The price-and-access landscape varies substantially between the two cities — and varies more by clinic and indication, within each city, than between them. A 2021 review in Health Policy compared the two frameworks on regulatory architecture and noted, in measured terms, that each has solved problems the other has not yet quite addressed, and that the comparison rewards careful reading on both sides. The cosmopolitan patient who has read both portals before booking, and who has held the convergences and divergences in view, has set the shape of the consideration correctly. The reader who has spent an evening in Causeway Bay weighing one trip against the other will, in the editorial reading, find the question resolves less on jurisdictional comparison than on the indication and protocol the candidate clinic in either city has actually walked through at consultation — and the candidate clinic that walks the patient through both architectures, frankly and without territorial pride, is generally the one operating at the higher register on either side of the East China Sea.

How the two compare on practical dimensions

The categorical comparison below sets out the dimensions the cosmopolitan patient is most likely to weigh between the two jurisdictions, set in editorial register rather than as a recommendation. The reader is invited to read the table the way one would read a pair of hospitality guides — for what each jurisdiction offers in its register, not for what is best in the abstract.

Frequently asked questions

The following questions are the ones that arrive most regularly in the inboxes of regenerative-medicine editors writing on the Korea-Japan question; the answers below are general, non-prescriptive, and intended for orientation rather than guidance on any specific treatment plan.

“The two frameworks read, on careful reading, less as a contrast and more as a pair of paired answers to the same regulatory question — and the cosmopolitan patient is best served by holding both readings in view, rather than collapsing the distinction into a verdict.”

An editorial reading of the comparative literature

Frequently asked questions

Is Japan more permissive than Korea for cellular therapy?

Permissive is the wrong word, on careful reading. Japan operates a dual-track architecture that admits a wider range of indication-protocol combinations through the ASRM certification pathway than Korea's single-track MFDS framework currently does. The Japanese architecture, however, imposes its own oversight requirements through the Special Committee for Regenerative Medicine system. The frameworks are differently drawn rather than one being permissive and the other strict.

Can I receive an FDA-style approved stem cell product in Korea?

Yes. MFDS — the Korean Ministry of Food and Drug Safety — operates an approval pathway recognisable in shape to the U.S. FDA or European EMA frameworks, and several allogeneic mesenchymal stem cell products carry current MFDS approval for specified indications. The cosmopolitan reader should ask the clinic for the product's MFDS approval documentation as a routine pre-consent step.

What does ASRM Class III mean in Japan?

Class III, under Japan's Act on the Safety of Regenerative Medicine, covers minimally manipulated autologous procedures of homologous use — the lowest-risk tier of the three-class architecture. Class III protocols still require Special Committee certification, notification to the regional bureau, and adverse-event reporting, but the committee review intensity is lighter than the Class I or Class II tiers. Patients should still ask for the certification documentation.

Which is faster — getting treatment in Seoul or Tokyo?

Same-week consultations are widely available in both cities through the foreign-patient registration channels, and the day-of treatment logistics differ more by clinic protocol and cell source than by jurisdiction. An autologous protocol, in either city, runs as a full-day visit; an allogeneic protocol as a shorter window. The comparative speed question is, in editorial reading, less salient than the comparative architecture question.

Is the language barrier different in Korea and Japan?

Both jurisdictions operate foreign-patient registration frameworks that include translation and interpretation requirements, though the lived experience varies considerably by clinic. The cosmopolitan reader should ask, at the booking stage, whether the consultation, consent, and aftercare communication will be conducted directly in the patient's preferred language or through interpretation, and which arrangement the clinic uses by default. Cantonese and Mandarin support is more widely available in Seoul than the casual reader might suppose.

Are clinical trials available to foreign patients in both jurisdictions?

Yes, in principle, though the practical arrangements vary. Korea operates a clinical-trial framework under MFDS that includes trials open to foreign patients at registered international clinical-trial centres. Japan operates clinical-trial pathways under both the PMD Act and ASRM framework, with eligibility set on a per-trial basis. The cosmopolitan reader interested in a trial-stage product should consult the relevant national registry — clinicaltrials.gov for some international listings, alongside the country-specific portals.

How should I choose between Korea and Japan for cellular therapy?

The choice, on careful reading, rarely turns on the regulatory comparison alone — it turns on the indication, the specific protocol on offer, the practitioner, the clinic's hospitality and language profile, and the wider trip logistics. Both jurisdictions operate substantive regulatory architecture and well-developed foreign-patient frameworks. The cosmopolitan patient who has read both portals, asked the right questions of both candidate clinics, and weighed the editorial reading alongside the regulatory one has set the shape of the choice correctly.